You are here :
Home
Healthcare
Payment Link for Sterlitech Corporation - Track etched Membrane Market & Pharmaceutical Filtration Market
Drug formulations
ATC
Antiinfectives for Systemic Use
Vaccines
Global Animal Vaccines Market Research Report
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
 |
Pasteurellosis Pasteurellosis and Vibriosis, Furunculosis and |
Upcoming |
|
|
Furunculosis Furunculosis and Vibriosis, Pasteurellosis and |
Upcoming |
|
|
North America Live attenuated vaccines The North American Live attenuated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $805 million in 2013 and expected to be $999 million by 2018 at a CAGR of 4.4%. Live attenuated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
European Live attenuated vaccines Market The European Live attenuated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $956 million in 2013 and expected to be $1253 million by 2018 at a CAGR of 5.6%. Live attenuated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Asian Live attenuated vaccines Market The Asian Live attenuated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $428 million in 2013 and expected to be $745 million by 2018 at a CAGR of 11.7%. Live attenuated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
North American Inactivated vaccines Market The North American Inactivated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $627 million in 2013 and expected to be $818 million by 2018 at a CAGR of 5.5%. Inactivated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
European Inactivated vaccines Market The European Inactivated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $744 million in 2013 and expected to be $1026 million by 2018 at a CAGR of 6.6%. European Inactivated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Asian Inactivated vaccines Market Research Report The Asian Inactivated Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $333 million in 2013 and expected to be $610 million by 2018 at a CAGR of 12.9%. Asian Inactivated Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
North American Sub-unit vaccines Market The North American Sub-unit Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $29 million in 2013 and expected to be $37 million by 2018 at a CAGR of 4.8%. North American Sub-unit Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
European Sub-unit vaccines Market The European Sub-unit Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $34million in 2013 and expected to be $46 million by 2018 at a CAGR of 6.0%. European Sub-unit Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Asian Sub-unit vaccines Market The Asian Sub-unit Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $15million in 2013 and expected to be $27 million by 2018 at a CAGR of 12.2%. Asian Sub-unit Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
North American Toxoid vaccines Market The North American Toxoid Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $149.8 million in 2013 and expected to be $177.3million by 2018 at a CAGR of 3.4%. Toxoid Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
European Toxoid vaccines Market The European Toxoid Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $177.9 million in 2013 and expected to be $222.4 million by 2018 at a CAGR of 4.6%. Toxoid Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
Asian Toxoid vaccines Market The Asian Toxoid Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans and the prevalence of tetanus and Diphtheria diseases. It was pegged at $79.6 million in 2013 and expected to be $132.2 million by 2018 at a CAGR of 10.7%. Toxoid Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
North American Conjugate vaccines Market The North American conjugate animal vaccine market is mainly driven by the growing prevalence of animal diseases and increasing incidences of zoonotic diseases in humans. It was valued at $64.3million in 2013 and is expected to reach $83.9 million by 2018 at a CAGR of 5.5% during the forecast period. The report analyzes the market by six segments/products: aquaculture, companion animal vaccines, equine, livestock, porcine, and poultry. The prominent players in the market are Sanofi-Aventis, Merck, Pfizer, Inc., Bayer AG, and Virbac. |
Upcoming |
|
|
European Conjugate Vaccines Market The European conjugate animal vaccine market is mainly driven by the growing prevalence of animal diseases and increasing incidences of zoonotic diseases in humans. It was valued at $76.4 million in 2013 and is expected to reach $105.3 million by 2018 at a CAGR of 6.6%. The report analyzes the market by six segments/products: aquaculture, companion animal vaccines, equine, livestock, porcine, and poultry. The prominent players in the market are Sanofi-Aventis, Merck, Pfizer, Inc., Bayer AG, and Virbac. |
Upcoming |
|
|
Asian Conjugate Vaccines Market The Asian conjugate animal vaccine market is mainly driven by the growing prevalence of animal diseases and increasing incidences of zoonotic diseases in humans. It was valued at $34.2 million in 2013 and is expected to reach $62.6 million by 2018, at a CAGR of 12.8% during the forecast period. The report analyzes the market by six segments/products: aquaculture, companion animal vaccines, equine, livestock, porcine, and poultry. The prominent players in the market are Sanofi-Aventis, Merck, Pfizer, Inc., Bayer AG, and Virbac. |
Upcoming |
|
|
North American Recombinant vaccines Market The North American Recombinant Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $118.1 million in 2013 and expected to be $151.5 million by 2018 at a CAGR of 5.1%. Recombinant Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
European Recombinant vaccines Market The European Recombinant Animal Vaccine Market is mainly driven by growing prevalence of Animal Diseases and increasing incidences of Zoonotic diseases in humans. It was pegged at $140.2 million in 2013 and expected to be $190 million by 2018 at a CAGR of 6.3%. Recombinant Animal Vaccine Market analyzes the market by 6 Products such as Aquaculture, Companion animal vaccines, Equine, Livestock, Porcine, and Poultry. The prominent players in the Market are Sanofi Aventis, Merck, Pfizer, Bayer, and Virbac. |
Upcoming |
|
|
North American DNA vaccines Market The North American DNA animal vaccine market, mainly driven by the growing prevalence of animal diseases and increasing incidences of zoonotic diseases in humans, was valued at $45.6 million in 2013 and is expected to reach $63.9 million by 2018, at a CAGR of 7.0% during the forecast period. The report on this market analyzes it under six segments/products: aquaculture, companion animal vaccines, equine, livestock, porcine, and poultry. The prominent players in the market are Sanofi-Aventis, Merck, Pfizer, Inc., Bayer AG, and Virbac. |
Upcoming |
Animal Vaccines
